Regencell Bioscience (NASDAQ:RGC) Rating Lowered to Sell at Wall Street Zen

Regencell Bioscience (NASDAQ:RGC) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Regencell Bioscience Stock Performance

NASDAQ RGC opened at $5.02 on Friday. Regencell Bioscience has a 52-week low of $4.51 and a 52-week high of $69.00. The company has a 50-day simple moving average of $16.25 and a 200 day simple moving average of $24.13.

Regencell Bioscience (NASDAQ:RGC) last released its earnings results on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.

Institutional Trading of Regencell Bioscience

A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new position in Regencell Bioscience in the 2nd quarter worth about $768,000. Squarepoint Ops LLC bought a new stake in shares of Regencell Bioscience during the second quarter valued at about $1,701,000. Bank of America Corp DE increased its position in shares of Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after buying an additional 17,143 shares during the period. Vident Advisory LLC lifted its holdings in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after buying an additional 11,866 shares in the last quarter. Finally, Hudson Bay Capital Management LP purchased a new stake in shares of Regencell Bioscience in the fourth quarter worth about $275,000. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.